Introduction
Considerable effort continues in the search for effective therapy for acquired immunodeficiency disease syndrome (AIDS), caused by infection with human immunodeficiency virus (HIV). Mortality due to this disease results largely from multiple opportunistic infections and neoplasms due to the underlying severe immune suppression. The virus encodes a RNA-dependent DNA polymerase (reverse transcriptase, Rl) active in early stages of cell infection, which provides a target for antiviral therapy. Nucleoside Received 2 July,1990; revised 17 September, 1990 . 'For correspondence.
Tel. (919) 966-6781; Fax (919) 966-3015. analogues comprise one class of compounds with activity in vitro against HIV. Included in this group are 3' -azido-3'-deoxythymidine (AZl), the only approved drug for treatment of AIDS, and several others, including 2',3'-dideoxycytidine, 2',3' -dideoxyinosine, 2',3' -dideoxycytidine, and 2' ,3' -didehydro-2' ,3' -dideoxythymidine (Mitsuya and Broder, 1986; Hamamoto et al., 1987; Hartmann et al., 1987; Balzarini et al., 1987) .
Clinical trials with AZT show beneficial results in decreasing mortality of AIDS patients and in some clinical parameters (Fischl et aI., 1987) ; however, severe sideeffects develop, particularly bone marrow suppression, often necessitating dosage reduction or cessation . In addition, AZT-resistant HIV has been isolated from AZT-treated patients Larder and Kemp, 1989) , increasing the need for alternative therapy.
Combinations of drugs which would result in an equivalent antiviral effect while reducing overall toxicity would be of great interest. One reported in vitro synergistic combination is that of AZT and acyclovir (ACV) in ATH8 . cells (Mitsuya and Broder, 1987) and in fact clinical trials have been conducted in Europe and in the USA using this combination of drugs. As acyclovir has little anti-HIV activity by itself, we examined several other guanosine analogues, and a combination of the most effective of these with AZT against HIV replication in vitro.
Results

Nucleoside analogues
C3 cells were used in screening the 11 compounds for activity against HIV replication, as assayed by the production of reverse transcriptase (Rl) activity in the supernatant medium at days 6-7 post-infection (p.l.), The compounds fell into groups according to activity, as seen in 
Drug combinations
In many experiments, inhibition by ACV alone was not sufficient to permit analysis of the data from combinations of drugs for synergism by the Chou and Chou (1987) method. To generalize the results, we tested three T-cell lines, C3,Jurkat, and CEM, with this combination of drugs.
In two experiments in Jurkat cells, the addition of a 100-, 250-, or 500-fold molar excess of ACV to AZT did not significantly alter the dose-response of virus replication when compared to that of AZT alone (Fig. 1A, B ). Likewise, the addition of a 100-or 250-fold molar excess of ACV to AZT did not significantly alter virus replication in CEM cells (Fig. 1C ). The ACV concentrations in these experiments were :::;30 fLM, well below a cytotoxic level. The ECsos calculated for either AZT alone or AZT plus ACV from these three experiments were virtually identical when the AZT plus ACV data were analysed by AZT concentration (data not shown).
Due to the reported synergism of acyclovir and AZT in vitro and the ongoing clinical trials of this combination, we tested the combination of three compounds from the most active group (AZG, DOG and carbovir) with AZT, as well as ACV plus AZT, against HIV replication in vitro: These experiments were set up by the constant ratio method. The ratios to be used were chosen to be close to the ratio of the ECgos of the two drugs involved (AZT plus DOG, AZG, or carbovir); for the combination of ACV and AZT, lower ratios were chosen due to the very large ratio between actual ECgos or ECsos.
Virus production in an experiment with C3 cells was assayed by RT activity and p24 concentration in the supernatant medium at 6-7 days p.i. The raw data for RT and p24 were converted to fraction affected [(100-% decrease)/100] (F,.), and software was used to determine the more conservative mutually non-exclusive combination indices ( Table 2 ). The combination of acyclovir and AZT in this experiment showed mainly additive to antagonistic effects, as evidenced by 5 of 9 points by RT data and 5 of 8 points by p24 data yielding combination index (CI) values >1.0, from both constant ratios used ( Table 2 ). The isobolograms of both sets of combinations show the same outcome; the ACV pius AZT points are near or above the lines for both RT and p24 data ( Fig. 2A, B We have examined 11 guanosine and other nucleoside analogues for their anti-HIV activity in vitro activity, and find they separate into three groups by activity. Some of these have been previously published with the use of various cell lines (McCormick et al., 1984; Mitsuya and Broder, 1986; Hartmann et al., 1987; Vince et al., 1988; Pauwels et al., 1988) . Acyclovir, an acyclic analogue of guanosine, has been recognized as a potent and selective inhibitor of herpesviruses (Elion et al., 1977) , and much interest has been shown in deriving active congeners (Boryski et al., 1988) .
Acyclovir was reported to inhibit HIV synergistically with AZT in ATH8 cells (Mitsuya and Broder, 1987) . In three additional T-Iymphocyte lines (C3, Jurkat and CEM), we found only additive to antagonistic interactions between AZT and ACV. If the basis of proposed synergism requires the intracellular formation of acyclovir-triphosphate, then these results appear reasonable in view of the lack of
Discussion
Keystone, CO; S. Carter et al., manuscript submitted for publication).
The combinations of AZG plus AZT in Jurkat or C3 cells resulted in mainly additive to antagonistic combination indices (in Jurkats at 100: 1 or 10: 1 ratio of drugs, 5 of 6 CI between 0.8 and 1.24; in C3 cells, 3 of 4 CI between 1.2 and 1.6). Forthecombination of DOGplusAZT in 50: 1 and 10:1 ratios in Jurkat cells, the CI were between 0.7 and 7.5; in CEM cells, 5 of 9 CI were between 0.6 and 0.85 and 3 of 9 CI were >3. The outcomes of these experiments did not vary greatly from cell line to cell line, supporting the idea that lack of synergism is not due to an unusual characteristic of a single T-cell line. virus-infected cells in 0.5 mM ACV showed extensive conversion to the triphosphate form (Elion et a/., 1977) .
Other groups have also been unable to reproduce the synergism of these two drugs in lymphocyte cell culture (M. Baba, Rega Institute, Belgium; H. Nakashima, Yamaguchi University, Japan; D. Averett, Burroughs Wellcome, NC, personal communications). Treatment of AIDS patients with AZT alone has resulted in side-effects such as anaemia and neutropenia; some patients are forced to reduce the dosage or discontinue its use altogether . For these patients, a combination of a much lower dose of AZT with another drug may prove more tolerable, while still producing an equivalent antiviral effect to help prevent reinfection of new CD4+ lymphocytes or other cells.
AZT alone (and most probably most nucleoside analogues) is unable to stop production of virus from already infected lymphocytes in vitro (Nakashima et el., 1986) or to completely prevent new infection of susceptible lymphocytes in vitro (Smith et a/., 1987) . In addition, Ho et at. (1989) recently reported that AZT -treated patients show decreased levels of virus in plasma, but constant levels of cell-associated virus by quantitative isolation methods. Since virus continues to be made in affected persons treated with AZT alone, with the demonstrated potential for AZT-resistant virus to be formed in vivo Larder and Kemp, 1989) , it is probable that a combination of two (or more) drugs would be beneficial in preventing the emergence of drug resistance, if this proves to be a clinical problem.
The combination of AZT plus a carbocyclic guanosine analogue, carbovir, has been shown to be synergistic against HIV in T-cell lines as well as in primary peripheral blood mononuclear cells (S. Carter et a/., manuscript submitted for publication). Other combinations of drugs (interferon-alpha and AZT, Hartshorn et el., 1987; phosphonoformate and interferon, Hartshorn et a/., 1986, ribavirin and DDA or DOG, Baba et el., 1987; PMEAand AZT, Smith et a/., 1989) have also shown synergism against HIV, whereas ribavirin and AZT have an antagonistic effect against HIV replication (Baba et a/., 1987; . The use of acyclovir plus azidothymidine was reported to have resulted in fewer deaths in AIDS patients in the European-Australian study (D. Cooper et a/., International AIDS Therapy, 19 June, 1990); however, this result may be due to the anti-herpesvirus activity of the acyclovir acting in concert with the anti-retroviral agent, AZT.
Materials and Experimental procedures
Virus and cells
The LAVstrain of HIVwas obtained from L. Montagnier, Institut Pasteur, Paris, France, and stocks were prepared in H9 or 03 cells. The humanT-cell line H9 (obtained from R. Gallo, National Cancer Institute, Bethesda, MD) was grown in RPMI-1640 with 8% foetal calf serum.C3 cells harbouring latent HTLV-II (Popovic et al., 1984;  obtained from W. M. Mitchell,Vanderbilt University, Nashville, TN), CEM cells (fromS. Carter,GlAXO Inc., Research Triangle Park, NC) and Jurkat cells (obtained from NIAIDAIDS Reference Reagent Repository Program, NIH, Bethesda, MD) were grown in the same medium. Cells were infected for drug experiments with the LAVstrainof HIV(at0.01 TCIDsoicell) in the presenceof 2 fL9 DEAE-dextran per ml for 1h, then washedtwice in mediumto removeexcessvirus. After this washing,aliquots of 5 x 10 4 (C3) or 10 s (Jurkat) cells per condition were set up in 48-well plates. Mock-infected cells were treated similarly with DEAE-dextran in parallel. For C3 and Jurkat cells, supernatant medium samples were taken at Day 6 or 7, when the positive control was at its peak.
Test compounds
Acyclovir (ACV) (Elion et al., 1977) and 10 other compounds (2',3'-dideoxycytidine (DOC); carbovir [(1 R-cis)-2-amino-1 ,9dihydro-9[4-hydroxymethyl)-2-cyclopenten-1-yl]-6H -purin -6one]; 3'-azido,-2',3'-dideoxyguanosine (AZG); 2',3'-dideoxyguanosine (DOG); 2',3'-dideoxyinosine (001); 2',3'-dideoxyriboside of 2,6-diaminopurine (DD-DAP); 2' ;3'-dideoxyadenosine (DDA); ribavirin; 759U (DHPG or 9-(1,3-dihydroxy-2-propoxymethyl)guanine); 515U (6-deoxyacyclovir) were obtainedfrom M. St Clair, and 3'-azido-3'-deoxythymidine (AZl) was kindly provided by S. Lehrman Nusinoff, both of Burroughs Wellcome Co., Research TrianglePark, NC.
Drug toxicity
Cellviabilitywas determined by exclusionof trypan blue dye. For growth curves, several aliquots of cells were set up in multiwell plates in each different drug concentration, and counted daily by Coulter counter.
Reverse transcriptase assay
Virus-associated reverse transcriptase activity was assayed in duplicate 50-fLl reactions containing30fLl of clarified unconcentrated supernatant mediumand 5 fLCi rH]-dTIP (specificactivity 60-80 Ci mrnol": Amersham Corp,ArlingtonHeights,IL)with the addition (final concentrations) of 10mM Tris-HCI, pH 7.5, 8mM MgCI 2, 10mM dithiothreitol, 0.5% Triton X-100, 50fL9 of poly(A) per ml, and 10fL9 of 0Iigo(dl)12-18 (Pharmacia Inc, Piscataway, NJ) per ml. After incubation at 37°C for 45 min, 40 fLl of each duplicate reaction were spotted onto DE81 paper (Whatman Inc, Maidstone, Kent, UK), washed, and counted as described previously (Smith et al., 1987 (Smith et al., , 1989 .
p24 antigen determinations
The concentration of viralp24 antigenin the supernatantmedium was determined by p24 ELISA assay, as described by the manufacturer (Dupont, NENResearch Products, Boston, MA).
I
Synergy calculations
Dose-effect relationships were analyzed by the median effect equation (Chou and Talalay, 1984; Chou and Chou, 1988) : log (falf u ) = m log D -m log D m, where Fa and fu are the fractions affected and unaffected by dose D. D m is the dose required to produce the median effect (or EC so ), and m is the slope of the median effect plot. The synergism, summation, or antagonism of two drugs was analysed by the multiple drug effect analysis of Chou and Talalay (1984) . The interaction effect was determined quantitatively by the combination index (CI), defined as: *u = 0 for mutually exclusive drug effect; a = 1 for mutually non-exclusive drug effect. Xalone = concentration of drug x which giving a certain percentage of RT inhibition. Xcombo = concentration of drug x which in combination with drug y gives a certain percentage of RT inhibition. CI values of <1 indicate synergism, CI values >1 indicate antagonism, and CI values = 1 indicate additive effects of the two drugs. Combination indices were not calculated from data where Fa> 0.99. The more conservative mutually non-exclusive CI were used when the slopes were not equal to 1. Isobolograms for EC so , EC 7 0 , and ECgo levels were also used to depict synergy of combined drug effects (Elion et al., 1954) . For these graphs, if the points representing the combinations of drugs fall under the line, the combination is considered synergistic; if above the line, antagonistic.
Note added in proof
In a recent report of a pilot clinical trial, Collier et el. found no evidence for in vivo synergism between AZT and acyclovir as measured by a change in the levels of HIV antigenemia, plasma viremia, CD4 lymphocyte counts, or clinical findings.
Collier, A.C. et al. (1990) .A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 323: 1015-1021.
